Medivir AB (publ) (MVRBF) Stock Price, News & Analysis

Company Overview

Medivir AB (publ) is a Swedish clinical-stage biotechnology company focused on developing medicines for cancer. The company’s research is centered on targeted therapies designed to act selectively in tumor tissue while limiting exposure to healthy cells.

Medivir’s lead drug candidate is fostroxacitabine (MIV-818), an orally administered nucleotide-based therapy being developed for primary liver cancer, including hepatocellular carcinoma. The company has evaluated fostroxacitabine both as a standalone treatment and in combination with other cancer therapies. Its broader research activities have included programs involving protease inhibitors and other targeted drug technologies.

The company has historical roots in antiviral drug discovery and was involved in the development of the hepatitis C treatment simeprevir, which was subsequently commercialized through a partnership with Janssen and approved in multiple markets. Medivir is based in Sweden and develops its programs for potential use in international oncology markets, working with external partners and clinical research organizations as appropriate.

Key Stats

• Today's Range: $0.82 to $0.82
• 50-Day Range: $0.82 to $0.82
• 52-Week Range: $0.68 to $0.82
• Volume: N/A
• Average Volume: 925 shs
• Market Capitalization: N/A
• P/E Ratio: 0.03
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MVRBF
• CIK: N/A
• Web: www.medivir.com
• Phone: (685) 468-3100
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A